OVERVIEW

Founded in September 2020 by Philippe Van Wesepoel and Jean François Plucker, OLYS Pharma is an innovative biotech aiming to improve the quality of life of patients suffering from chronic painful inflammatory conditions.

Concretely, the Start-Up’s research focuses on cell physiology and physiopathology, ionic pathways involvement in particular, to develop efficient well tolerated topical/transdermal ionic modulator treatments both restoring physiological innate immune response capacity and cell/tissue homeostasis, favoring patients’ recovery.

PHILOSOPHY

Beyond Thinking for Better Health

Taking a fresh look, get back to basics by deciphering cellular physiology and pathophysiology, looking beyond the obvious, continual questioning, we are driven by an unwavering desire to learn and understand.

This is how OLYS Pharma works on the development of innovative and ever more effective treatments to restore the quality of life of suffering patients.

OLYS Pharma defends strong and firmly anchored values.

“Guided by passion and curiosity, our pursuit is excellence. We build bridges and ethics are found in everything we do. We innovate, walk outside the box and create entirely new technology”.

THE FOUNDERS

JF. Plucker
JF. PluckerCo-fondateur & COO
Partner of an intellectual property firm in Brussels, Jean François Plucker worked for clients in many countries, before moving to the United States where he specialized in technology transfers between university or federal laboratories and private industrial companies. Combining scientific and economic logics became its strength, where the two logics usually clash. He puts his international experience at the service of humanly useful and economically promising projects. Co-founder of OLYS Pharma, he brings a seasoned experience in management, international trade and intellectual property in the development of the Start-Up.
Ph. Van Wesepoel
Ph. Van WesepoelCo-fondateur & CSO
With a scientific background and an MBA, Philippe Van Wesepoel has experience in different therapeutic areas of the pharmaceutical industry demonstrating both his practicality and his scientific rigor. He is passionate about cellular physiology, sensing and signaling channels, and their evolution over time and across species, on which he relies to develop effective and well-tolerated treatments, both by restoring the physiological innate immune capacity of cells and respecting homeostasis.

BOARD OF DIRECTORS

Ph. Van Wesepoel
Ph. Van WesepoelAssociate Director - CSO
OLYS Pharma
Jean François Plucker
Jean François PluckerAssociate Director - COO
OLYS Pharma
Sébastien Gillig
Sébastien GilligVice-President Finance Europe
ECOLAB